MicroVision MOVIA lidar gains support on NVIDIA DRIVE AGX platform
SALT LAKE CITY - LifeVantage Corporation (NASDAQ:LFVN), currently trading at $12.60 and according to InvestingPro analysis slightly undervalued, announced Tuesday that its MindBody GLP-1 System showed an average increase of over 200% in GLP-1 hormone levels across participants in combined clinical trials.
The health and wellness company, which boasts impressive gross profit margins of 80% and has shown strong revenue growth of 8.2% over the last twelve months, said the latest results, which combine data from an April 2025 trial with findings from fall 2024, represent an improvement from the previously reported 140% increase in GLP-1, a hormone that supports appetite regulation and metabolic health.
According to the press release, the 12-week clinical studies showed participants lost an average of 11 pounds, with some losing up to 25 pounds. The company reported that participants experienced up to 9% decrease in total body fat percentage, up to 24% decrease in visceral fat, and up to 6% increase in skeletal muscle.
The studies also documented changes in participants’ eating behaviors, with 95% reporting decreased sugar cravings, 89% eating less at meals, and 86% feeling less hungry.
Lisa Barnes, Vice President of R&D and Regulatory at LifeVantage, said the findings "validate the effectiveness of our natural approach to stimulating the body’s own production of GLP-1 and other key metabolic hormones."
The company also completed an independent 12-week human clinical trial of its international formula, called the MB System, which reportedly demonstrated similar results.
LifeVantage, which describes itself as a pioneer in nutrigenomics, trades on the Nasdaq exchange and is headquartered in Lehi, Utah.
The information in this article is based on a company press release statement.
In other recent news, LifeVantage Corporation reported its financial results for the third quarter of 2025, revealing a notable earnings beat. The company posted an earnings per share of $0.26, which exceeded the forecasted $0.20. However, LifeVantage’s revenues fell short of expectations, coming in at $58.4 million compared to the anticipated $60.99 million. These developments highlight mixed results for the company, with earnings surpassing projections but revenues not meeting estimates. Despite the earnings beat, LifeVantage faced a sharp decline in its stock price during aftermarket trading. The company’s stock dropped significantly, although the focus here is on the earnings and revenue figures. These recent developments provide investors with crucial insights into LifeVantage’s financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.